Abstract
Background and Objectives Neurofilament light (NfL) appears a promising fluid biomarker in repeat-expansion spinocerebellar ataxias (SCAs), with piloting studies in mixed SCA cohorts suggesting that NfL might be increased at the ataxic stage of spinocerebellar ataxia type 1 (SCA1). We here hypothesised that NfL is increased not only at the ataxic stage of SCA1, but also at its – likely most treatment-relevant – preataxic stage.
Methods We assessed serum (sNfL) and cerebrospinal fluid (cNfL) levels of NfL in both preataxic and ataxic SCA1, leveraging a multicentric cohort of 40 SCA1 carriers (23 preataxic, 17 ataxic) and >80 controls, and clinical follow-up data including actually observed (rather than only predicted) conversion to the ataxic stage (11 carriers).
Results sNfL levels were increased with high age-corrected effect sizes at the preataxic (r=0.62) and ataxic stage (r=0.63), paralleling increases of cNfL levels. In preataxic subjects, sNfL levels increased with proximity to predicted ataxia onset, with significant sNfL elevations already 5 years before onset, and confirmed in preataxic subjects with actually observed ataxia onset. sNfL increases were detected already in preataxic SCA1 subjects without volumetric atrophy of cerebellum or pons, suggesting that sNfL might be more sensitive to early preataxic neurodegeneration than the currently known most change-sensitive regions in volumetric MRI. Using longitudinal sNfL measurements, we estimated sample sizes for clinical trials using the reduction of sNfL as endpoint.
Conclusions sNfL levels might thus provide easily accessible peripheral biomarkers in both preataxic and ataxic SCA1, allowing stratification of preataxic subjects regarding proximity-to-onset, early detection of neurodegeneration even before volumetric MRI alterations, and potentially capture of treatment response in clinical trials.
Competing Interest Statement
CW has nothing to disclose. DM has served as consultant for Biogen. LS has nothing to disclose. HH has nothing to disclose. MR has nothing to disclose. TK received consulting fees from Biohaven, Roche, UCB, Uniqure, and Vico Therapeutics. AD is currently receiving grants from the National Institute of Health (RO1), French National Hospital Clinical Research Program (PHRC), Agence nationale de la recherche (ANR), Triplet Therapeutics, Biogen and Verum, serves on the advisory boards of Roche, Triplet Therapeutics, and Biogen, and holds partly a patent on anaplerotic therapy of Huntington's disease and other polyglutamine diseases (B 06291873.5). AF has nothing to disclose. BM has nothing to disclose. RS has nothing to disclose. KR has received grants from the German Federal Ministry of Education and Research (BMBF 01GQ1402, 01DN18022), the German Research Foundation (IRTG 2150), Alzheimer Forschung Initiative e. V. (NL-18002CB), Friedreich's Ataxia Research Alliance (FARA) and honoraria for presentations or advisory boards from Biogen and Roche. HJ has nothing to disclose. MS received consultancy honoraria from Orphazyme Pharmaceuticals and Janssen Pharma-ceuticals, both unrelated to the current project and manuscript. He received consultancy honoraria also from Ionis Pharmaceuticals on trial planning in SCA1, yet also unrelated to the current project and manuscript.
Clinical Trial
The EuroSCA cohort was not registered by the respective research consortium. The RiSCA cohort is registered on clinicaltrials.gov (NCT01037777).
Funding Statement
We thank all participants and their families for their contribution. CW, LS, TK, AD, RS and MS are members of the European Reference Network for Rare Neurological Diseases Project ID No 739510. This work was supported by the Horizon 2020 research and innovation programme (grant 779257 Solve-RD to MS and RS), the Clinician Scientist Program of the Medical Faculty Tuebingen (480-0-0 to CW, and 459-0-0 to DM), the Bundesministerium fuer Forschung und Bildung (BMBF) through funding for the TreatHSP network (01GM1905 to RS), the European Joint Programme on Rare Diseases (EJP RD) under the EJP RD COFUND-EJP No. 825575 (PROSPAX consortium, to MS, RS and AD, with MS and RS hereby supported by the Deutsche Forschungsgemeinschaft (DFG)). BM was supported by National Scientific Research Programme (NKFI) K 138669 and EFOP 3.6.1-16.2016.00004. The funding sources had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. We thank Elke Stransky for technical assistance and Christoph Kessler for support in setting up the CSF NfL reference cohort.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University of Tuebingen approved the study (AZ 103/2017BO2). All subjects provided written informed consent before participation according to the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The anonymised data of this article can be accessed on reasonable request addressed to the corresponding authors.
